SPESE IN RICERCA E SVILUPPO COME DA BILANCIO AL 31/12/2019 LE SPESE SOSTENUTE DALLA SOCIETA'PER R&S E BREVETTI AMMONTANO RISPETTIVAMENTE: SPESE R&S 1.533.796,00 DI CUI CAPITALIZZATE EURO 896.276,00; SPESE BREVETTI (CAPITALIZZATI) EURO 210.659,00 VOLUME SPESA = 8,95% DEL VALORE DI PRODUZIONE
Titles and professional experiences of partners and working staff
TITOLO: DOTTORE DI RICERCA N.5 SUBORDINATI E N.6 NON SUBORDINATI TITOLO: LAUREA MAGISTRALE N.8 SUBORDINATI E N.4 NON SUBORDINATI TITOLO: LAUREA PRIMO LIVELLO N. 2 SUBORDINATI E N.2 NON SUBORDINATI TITOLO: TECNICO DI LABORATORIO N.3 SUBORDINATI
Professional relationships with incubators, investors and research universities
FOND.S.LUCIA INNOVAL ISR SRL OSP.S.ANDREA UNIVERSITA' DEGLI STUDI DI FIRENZE UNIVERSITA' DEGLI STUDI DI MESSINA UNIVERSITA' DEGLI STUDI DI NAPOLI UNIVERSITA' DEGLI STUDI DI PADOVA UNIVERSITA' DEGLI STUDI DI ROMA
List of privative rights on industrial, intellectual property
EP1844784 DEL 21/04/2010 - US 8,546,352 DEL 01/10/2013 - IT0001415028 DEL 09/04/2015 - EP 2475352 DEL 17/06/2015 - EP 2821083 DEL 29/06/2016 - IT0001423067 DEL 05/07/2016 - JP5982016 DEL 05/08/2016 - EP2921167 DEL 17/08/2016 - IT0001423748 DEL 22/08/2016.
Requirements for technological innovation
Innovative SMEs Section
Number of Employees Range
Subscribed Capital Range
DATA FILLED USING DIGITAL SIGNATURE
by the legal representative RAFFAELLA DELLA VALLE on 2020-07-29
Epitech Group is a SME whose strategic plan is focused on the development of a pharmacology based on naturally active ingredients with the capacity to enhance endogenous protective systems. Epitech was founded by specialists in the field of lipid pharmacology whose activities have been, and continue to be, devoted to the identification, study and validation of new pharmacological modulatory mechanisms applied to the development, production and marketing of therapeutic products based on the use of natural substances to control pathological states associated with chronic neuro-inflammatory processes.
GEOGRAPHIC AREA OF INTEREST
Large-scale retail channel
BUSINESS MODEL AND SOURCE OF PROFITS
Epitech Group applies a vertical business model focused on the identification and development of natural therapeutic agents marketed as Special Foods for Medical Purposes. The breath of Epitech’s intellectual property portfolio is designed to allow the Company to fully maximize the value of each invention. The entrepreneurial strategy by which these patented innovations have been built up over the years includes management of a ‘network’ research system based on distinct, non-overlapping competencies across a series of centers of excellence that encompass both pre-clinical and clinical trials in line with the Company’s core interests. The Company’s internal structure, in turn, coordinates the establishment, implementation and disclosure of knowledge gathered from these research projects directing them, as far as possible, towards the Company’s interests. These internal structures deal also with the clinical application of the research findings, in order to identify products suitable for entry into national and international markets. Epitech internationalization processes come from patents’ licensing.
Holding licenses owned intellectual with the entity and/or to the founder and/or third parties
Short description of the aspects of innovation that characterize the business enterprise
The value of Epitech’s patents is leveraged by capitalizing on research and development that uses bio- and nano-technological techniques to achieve bioactive principles, or composites, with reduced particle size and superior bioavailability / effectiveness. Particularly important is the development of controlled-release formulation technologies that optimizes absorption and tissue distribution of the active ingredients.
A fundamental, innovative feature of the bioactive molecules and compositions developed by Epitech is their ability to act with the framework of the mechanism ALIA (Autacoid Local Injury Antagonism), an acronym coined for the first time in 1996 by the Nobel Prize laureate Rita Levi-Montalcini. This concept defines the agent’s ability to promote the resolution of neuro-inflammatory processes by regulating the activity of non-neuronal cells, primarily mast cells and microglia, thereby promoting recovery of tissue homeostasis.
There are no loans and / or investments for the company to report